Alimera Sciences, Inc. (ALIM) financial statements (2021 and earlier)
Company profile
| Business Address |
6120 WINDWARD PARKWAY ALPHARETTA, GA 30005 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 11 | 9 | 13 | 24 | 31 | 31 | 77 | ||
| Cash and cash equivalents | 11 | 9 | 13 | 24 | 31 | 31 | 77 | ||
| Restricted cash and investments | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Receivables | 17 | 19 | 17 | 11 | 14 | 10 | 1 | ||
| Inventory, net of allowances, customer advances and progress billings | 3 | 1 | 2 | 2 | 0 | 2 | 2 | ||
| Inventory | 3 | 1 | 2 | 2 | 0 | 2 | 2 | ||
| Deferred costs | 1 | ||||||||
| Other undisclosed current assets | 4 | 3 | 2 | 2 | 2 | 3 | 3 | ||
| Total current assets: | 35 | 33 | 35 | 39 | 47 | 45 | 83 | ||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | |||
| Operating lease, right-of-use asset | 1 | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Property, plant and equipment | 2 | 1 | 1 | 2 | 3 | 2 | |||
| Intangible assets, net (including goodwill) | 13 | 15 | 17 | 19 | 21 | 23 | 24 | ||
| Intangible assets, net (excluding goodwill) | 13 | 15 | 17 | 19 | 21 | 23 | 24 | ||
| Deferred income tax assets | 1 | 1 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Deferred tax assets, net | ✕ | ✕ | 0 | 0 | |||||
| Other undisclosed noncurrent assets | 1 | 1 | 1 | 0 | (0) | ||||
| Total noncurrent assets: | 16 | 18 | 19 | 21 | 23 | 25 | 26 | ||
| TOTAL ASSETS: | 51 | 50 | 54 | 60 | 70 | 70 | 109 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 11 | 12 | 10 | 9 | 9 | 8 | 6 | ||
| Accounts payable | 7 | 7 | 6 | 6 | 5 | 4 | 5 | ||
| Accrued liabilities | 3 | 5 | 4 | 4 | 4 | 4 | 1 | ||
| Interest and dividends payable | 0 | ||||||||
| Debt | 2 | 0 | 0 | 0 | 0 | 32 | 1 | ||
| Derivative instruments and hedges, liabilities | 0 | 16 | |||||||
| Deferred tax liabilities | ✕ | ✕ | 0 | ||||||
| Other undisclosed current liabilities | 0 | (13) | |||||||
| Total current liabilities: | 12 | 12 | 10 | 10 | 9 | 40 | 10 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 43 | 0 | 0 | 35 | 33 | 1 | 33 | ||
| Long-term debt, excluding current maturities | 42 | 34 | 33 | 33 | |||||
| Finance lease, liability | 1 | 0 | ✕ | ✕ | ✕ | ✕ | ✕ | ||
| Capital lease obligations | ✕ | ✕ | 0 | 0 | 0 | 1 | 0 | ||
| Liabilities, other than long-term debt | 4 | 4 | 3 | 1 | 2 | 1 | 0 | ||
| Other liabilities | 4 | 4 | 3 | 1 | 2 | 1 | 0 | ||
| Total noncurrent liabilities: | 46 | 4 | 3 | 35 | 36 | 1 | 33 | ||
| Total liabilities: | 59 | 16 | 14 | 45 | 45 | 41 | 44 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | (8) | (4) | 3 | 15 | 26 | 26 | 50 | ||
| Common stock | 0 | 0 | 1 | 0 | 0 | ||||
| Additional paid in capital | 366 | 350 | 346 | 342 | 331 | 299 | 293 | ||
| Accumulated other comprehensive loss | (1) | (1) | (1) | (1) | (1) | (1) | (1) | ||
| Accumulated deficit | (393) | (388) | (377) | (399) | (377) | (344) | (313) | ||
| Warrants and rights outstanding | 0 | 4 | 4 | ||||||
| Other undisclosed stockholders' equity attributable to parent | 19 | 30 | 30 | 73 | 73 | 72 | 70 | ||
| Total stockholders' equity: | (8) | (4) | 3 | 15 | 26 | 26 | 50 | ||
| Other undisclosed liabilities and equity | 39 | 38 | 3 | 16 | |||||
| TOTAL LIABILITIES AND EQUITY: | 51 | 50 | 54 | 60 | 70 | 70 | 109 | ||
Income statement (P&L) ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 51 | 54 | 47 | 36 | 34 | 22 | 8 | |
| Cost of revenue (Cost of Goods and Services Sold) | (7) | (7) | (3) | (2) | (2) | (1) | ||
| Other undisclosed gross profit | (5) | |||||||
| Gross profit: | 44 | 47 | 42 | 32 | 32 | 21 | 7 | |
| Operating expenses | (44) | (53) | (52) | (49) | (60) | (60) | (40) | |
| Operating loss: | (1) | (5) | (10) | (16) | (28) | (39) | (33) | |
| Nonoperating income (expense) (Foreign Currency Transaction Gain (Loss), before Tax) | 0 | (0) | (0) | 0 | (0) | (0) | (1) | |
| Interest and debt expense | (5) | (5) | (7) | (6) | (8) | (5) | (3) | |
| Other undisclosed income from continuing operations before equity method investments, income taxes | 0 | 3 | 13 | 0 | ||||
| Loss from continuing operations before equity method investments, income taxes: | (5) | (10) | (16) | (22) | (33) | (31) | (36) | |
| Other undisclosed loss from continuing operations before income taxes | (0) | |||||||
| Loss from continuing operations before income taxes: | (5) | (10) | (16) | (22) | (33) | (31) | (36) | |
| Income tax expense (benefit) | 0 | (0) | (0) | (0) | (0) | (0) | (0) | |
| Net loss attributable to parent: | (5) | (10) | (16) | (22) | (33) | (31) | (36) | |
| Preferred stock dividends and other adjustments | 38 | |||||||
| Undistributed earnings (loss) allocated to participating securities, basic | 4 | ✕ | ✕ | ✕ | ||||
| Other undisclosed net loss available to common stockholders, basic | (4) | (1) | ||||||
| Net income (loss) available to common stockholders, diluted: | (5) | (10) | 22 | (22) | (33) | (31) | (37) | |
Comprehensive Income ($ in millions)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (5) | (10) | (16) | (22) | (33) | (31) | (36) | |
| Other comprehensive income (loss) | (0) | (0) | 0 | (0) | (0) | (0) | ||
| Comprehensive loss: | (5) | (11) | (17) | (22) | (33) | (31) | (36) | |
| Other undisclosed comprehensive income, net of tax, attributable to parent | 1 | |||||||
| Comprehensive loss, net of tax, attributable to parent: | (5) | (11) | (17) | (22) | (33) | (31) | (36) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.